Degron Therapeutics pioneers the exploration and advancement of targeted protein degradation therapeutics through small molecule molecular glue degraders (MGDs). With a cadre of esteemed scientific minds and seasoned industry experts, Degron leverages its profound expertise to pinpoint and validate MGD targets, especially those pivotal in disease pathogenesis yet challenging to drug via traditional modalities.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.